Published in N Engl J Med on February 07, 2013
Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL) | NCT02109614
Effect of PCSK9 InhibitorS On Calcific Aortic Valve DiseasE (EPISODE) | NCT04968509
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes (2013) 2.09
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol (2016) 1.46
Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol (2014) 1.07
Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol (2014) 0.98
Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA (2014) 0.97
A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium). J Am Coll Cardiol (2014) 0.96
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol (2015) 0.92
The long non-coding HOTAIR is modulated by cyclic stretch and WNT/β-CATENIN in human aortic valve cells and is a novel repressor of calcification genes. PLoS One (2014) 0.92
Racial differences in the prevalence of severe aortic stenosis. J Am Heart Assoc (2014) 0.89
Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol (2015) 0.89
Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res (2013) 0.87
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovasc Drugs Ther (2016) 0.86
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res (2015) 0.85
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). J Am Heart Assoc (2016) 0.85
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res (2016) 0.85
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2014) 0.84
Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease. Public Health Genomics (2014) 0.84
Structure, function, and genetics of lipoprotein (a). J Lipid Res (2016) 0.83
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. Int J Epidemiol (2015) 0.83
Risk Stratification in Patients With Aortic Stenosis Using Novel Imaging Approaches. Circ Cardiovasc Imaging (2015) 0.82
Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arterioscler Thromb Vasc Biol (2015) 0.82
Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults. Heart (2016) 0.82
Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res (2015) 0.81
IL-10 genetic polymorphisms were associated with valvular calcification in Han, Uygur and Kazak populations in Xinjiang, China. PLoS One (2015) 0.81
Aortic Stenosis: Changing Disease Concepts. J Cardiovasc Ultrasound (2015) 0.81
Diagnosis and management of valvular aortic stenosis. Clin Med Insights Cardiol (2014) 0.80
Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol (2013) 0.80
Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. J Lipid Res (2015) 0.79
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo. Sci Rep (2014) 0.79
Calcific aortic stenosis. Nat Rev Dis Prim (2016) 0.79
Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res (2014) 0.79
Innate and Adaptive Immunity in Calcific Aortic Valve Disease. J Immunol Res (2015) 0.78
Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. Circ Cardiovasc Genet (2015) 0.78
Pathophysiology of valvular heart disease. Exp Ther Med (2016) 0.78
Assessment of risk factors for developing incident aortic stenosis: the Tromsø Study. Eur J Epidemiol (2014) 0.78
Lipoprotein (a): Coming of Age at Last. J Lipid Res (2016) 0.78
New Era of Lipid-Lowering Drugs. Pharmacol Rev (2016) 0.77
The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavík study. Int J Cardiol (2014) 0.77
Genetics of valvular heart disease. Curr Cardiol Rep (2014) 0.77
Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat Genet (2016) 0.77
The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis (2016) 0.76
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol (2016) 0.76
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation. J Vis Exp (2016) 0.76
Towards Increasing the Clinical Relevance of In Silico Methods to Predict Pathogenic Missense Variants. PLoS Comput Biol (2016) 0.76
Genetics of Lipid and Lipoprotein Disorders and Traits. Curr Genet Med Rep (2016) 0.76
Aortic valve calcification in 499 consecutive patients referred for computed tomography. Arch Med Sci (2015) 0.75
Providing Evidence for Subclinical CVD in Risk Assessment. Glob Heart (2016) 0.75
Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol (2016) 0.75
Impact of Valve Morphology on the Prevalence of Coronary Artery Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc (2016) 0.75
Biomarkers of Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol (2017) 0.75
Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. G3 (Bethesda) (2016) 0.75
Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol (2015) 0.75
A Genomics-Based Model for Prediction of Severe Bioprosthetic Mitral Valve Calcification. Int J Mol Sci (2016) 0.75
Integrated microRNA and messenger RNA analysis in aortic stenosis. Sci Rep (2016) 0.75
Shared genetic risk for sclerosis of valves and vessels. N Engl J Med (2013) 0.75
Cardiovascular disease prevention: lifestyle attenuation of genetic risk. Nat Rev Cardiol (2017) 0.75
Valvular disease: Lipoprotein(a) link to calcification. Nat Rev Cardiol (2013) 0.75
A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease. Circulation (2015) 0.75
Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study. J Int Med Res (2016) 0.75
Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification. J Am Coll Cardiol (2017) 0.75
Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study. Arterioscler Thromb Vasc Biol (2017) 0.75
Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. PLoS One (2017) 0.75
Relationship of bone mineral density with valvular and annular calcification in community-dwelling older people: The Cardiovascular Health Study. Arch Osteoporos (2017) 0.75
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Curr Diab Rep (2017) 0.75
A haplotype map of the human genome. Nature (2005) 105.70
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol (2002) 35.63
Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol (1990) 28.97
Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health (1951) 20.27
An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol (1979) 18.84
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med (1999) 8.14
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol (2007) 7.06
Mutations in NOTCH1 cause aortic valve disease. Nature (2005) 6.27
Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet (2001) 5.99
The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med (1993) 5.35
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA (2009) 4.42
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med (2000) 4.13
Aortic stenosis. Lancet (2009) 3.37
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol (1996) 2.60
Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation (2003) 2.39
Defining normal distributions of coronary artery calcium in women and men (from the Framingham Heart Study). Am J Cardiol (2008) 2.26
A potential basis for the thrombotic risks associated with lipoprotein(a). Nature (1989) 1.93
The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart (2001) 1.86
Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J (2003) 1.53
The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med (2002) 1.48
'Deep phenotyping': characterizing populations in the era of genomics and systems biology. Curr Opin Lipidol (2008) 1.46
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28
Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol (2011) 1.23
Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J Am Coll Cardiol (2010) 1.12
Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation (2003) 1.12
Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol (1995) 1.06
Evidence for a heritable component in death resulting from aortic and mitral valve diseases. Circulation (2004) 1.02
The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J (2004) 1.01
Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med (2008) 1.00
Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med (2003) 0.98
Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension (2007) 0.95
Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res (1996) 0.94
Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation (2006) 0.93
Lipoprotein (a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall. Chem Phys Lipids (1994) 0.89
Replication of genetic association studies in aortic stenosis in adults. Am J Cardiol (2011) 0.87
Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis (2007) 0.82
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (2008) 15.77
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med (2014) 12.79
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10